Uterine Fibroids: A Practical Caregiver and Family Guide

What Caregivers and Family Members Most Need to Know First

Uterine fibroids are noncancerous growths of the uterine muscle. They are common, they are not contagious, and malignant transformation (leiomyosarcoma) is rare, occurring in fewer than 1 in 1,000 cases of suspected fibroid. Still, their symptoms can be severe enough to cause iron-deficiency anemia, disrupt work and social life, and trigger significant anxiety about fertility and long-term health.

If someone you love has just been diagnosed, your first job is to understand why her symptoms are real and why "just waiting it out" is not always appropriate medical advice.

ACOG Practice Bulletin 228 defines uterine leiomyomas as "the most common benign uterine neoplasm" and identifies heavy menstrual bleeding, pelvic pain, and reproductive dysfunction as the primary indications for treatment. That guideline is the clinical foundation of everything in this article.

Understanding the Diagnosis

How Fibroids Are Found

Most fibroids are found during a routine pelvic exam or incidentally on ultrasound ordered for another reason. When a clinician suspects fibroids based on an enlarged, irregular uterus or reported heavy periods, the standard first step is transvaginal or transabdominal ultrasound. Sensitivity for detecting fibroids 1 cm or larger is high with ultrasound, but smaller intracavitary lesions may require saline-infusion sonohysterography (SIS) or hysteroscopy.

MRI is reserved for cases where the number, size, and location of fibroids matter for surgical or procedural planning, or where adenomyosis (a separate condition that can coexist) needs to be ruled out. MRI does not involve radiation and is safe for most women, including those who are breastfeeding.

Fibroid Location Changes Everything

Where a fibroid sits inside or on the uterus determines its symptoms and treatment options:

• Submucosal (inside the uterine cavity): most likely to cause heavy bleeding and pregnancy loss; usually treated with hysteroscopic removal.
• Intramural (within the uterine wall): most common; causes bulk symptoms, pelvic pressure, and urinary frequency when large.
• Subserosal (projecting outward): causes pelvic pressure, back pain, and bladder or bowel symptoms; less likely to affect the menstrual cycle directly.

This distinction matters when your family member is discussing treatment. A clinician recommending hysteroscopy for a submucosal fibroid is being appropriately targeted. Caregivers who understand this can help the person they support ask sharper questions.

Why Black Women Are Disproportionately Affected

Research published in the American Journal of Obstetrics and Gynecology shows that Black women develop fibroids earlier (often in their 20s), have larger and more numerous fibroids, and experience more severe symptoms than white women at the time of diagnosis. They also wait longer for treatment and are more likely to end up having a hysterectomy as their first definitive intervention, partly due to structural healthcare access issues.

If you are supporting a Black woman with fibroids, advocate actively for specialist referral and a thorough discussion of uterine-preserving options before hysterectomy is offered as the only solution.

How Fibroids Affect Women Across Every Life Stage

Understanding how fibroids behave differently at each reproductive stage helps caregivers give better-targeted support.

Reproductive Years (Teens Through Late 30s)

Fibroids are estrogen- and progesterone-sensitive. During the reproductive years, when both hormones are at their highest, fibroids grow most actively. A longitudinal study in Obstetrics and Gynecology found that fibroid growth rate averages about 9 percent per 6 months in premenopausal women, though this varies widely. Heavy periods can cause iron-deficiency anemia: fatigue, breathlessness on exertion, and difficulty concentrating are not just "bad periods" but physiological consequences of chronic blood loss. Supporting the woman in your life to get a ferritin level checked and take iron supplementation if needed is a concrete, low-barrier contribution you can make right now.

Trying to Conceive and Fertility

Submucosal fibroids that distort the uterine cavity are clearly associated with reduced implantation rates and increased miscarriage risk. The evidence for intramural fibroids not touching the cavity is more mixed. The ASRM Practice Committee concludes that submucosal fibroids should be removed before IVF, while the recommendation for intramural fibroids depends on size and cavity distortion.

Myomectomy (surgical fibroid removal leaving the uterus intact) is the fertility-preserving surgical option. Recovery from open abdominal myomectomy typically takes 4 to 6 weeks, during which a caregiver's physical help, including meal preparation, transportation, and light housework, is not optional luxury support but medical necessity.

Pregnancy

Fibroids do not disappear during pregnancy. A meta-analysis in the American Journal of Obstetrics and Gynecology found that women with fibroids have a significantly increased risk of preterm birth, placenta previa, fetal malpresentation, cesarean delivery, and postpartum hemorrhage compared with women without fibroids. Fibroids may enlarge rapidly in the first trimester due to surging estrogen and hCG, sometimes causing "red degeneration," a painful but self-limiting condition where the fibroid outgrows its blood supply.

Caregivers supporting a pregnant woman with fibroids should know that:

1. Increased pain episodes do not always mean an emergency, but they should always be reported to her obstetric team.
2. She may need more antenatal appointments than a standard pregnancy.
3. Cesarean section is more likely, so planning for a longer postoperative recovery is realistic, not pessimistic.

Myomectomy during pregnancy is almost never performed except in life-threatening situations, because blood loss risk is prohibitive.

Perimenopause

During perimenopause (typically the mid-to-late 40s), estrogen levels fluctuate erratically before eventually declining. Fibroids can temporarily enlarge during estrogen surges, causing a worsening of heavy bleeding in the years just before menopause, even when a woman assumes symptoms should be improving. This is one of the most clinically misunderstood periods: a woman in her late 40s with worsening bleeding does not automatically have endometrial cancer, but she does need evaluation to rule it out. ACOG recommends endometrial sampling for abnormal uterine bleeding in women 45 and older or in younger women with risk factors.

Family members can help by reducing the common tendency to dismiss worsening symptoms as "just menopause." Encourage evaluation. The distinction matters.

Post-Menopause

Once estrogen production drops sharply after the final menstrual period, fibroids typically shrink and become asymptomatic. A woman who tolerated her fibroids through menopause without major intervention often finds her symptoms resolve on their own within 1 to 3 years postmenopause. However, if fibroids grow after menopause, that is a red flag. ACOG guidelines state that postmenopausal growth warrants evaluation to exclude malignancy.

Hormone therapy for menopausal symptoms can cause some fibroid regrowth, though this is usually modest and does not always require stopping HRT. The decision is individualized.

Treatment Options: What You Need to Know as a Caregiver

Treatment choice depends on symptom severity, fibroid size and location, reproductive goals, and life stage. There is no single right answer, and watchful waiting (surveillance without active treatment) is appropriate for asymptomatic or mildly symptomatic fibroids.

Medical Management

Hormonal options include:

• Levonorgestrel IUD (Mirena): Reduces menstrual blood loss by up to 90 percent in many women and is a first-line option for women with intramural or subserosal fibroids who do not have significant cavity distortion. It does not shrink fibroids but controls bleeding effectively. A Cochrane review supports its use for heavy menstrual bleeding.
• GnRH agonists (leuprolide, goserelin): These create a temporary menopausal state, shrinking fibroids by 35 to 65 percent over 3 to 6 months. They are used most often to reduce fibroid size before surgery or to manage anemia preoperatively. Long-term use causes bone loss, so ACOG recommends limiting use to 6 months or adding back-therapy (low-dose estrogen plus progestin) when used longer.
• GnRH antagonists with add-back therapy (elagolix/estradiol/norethindrone acetate, brand name Oriahnn; relugolix/estradiol/norethindrone acetate, brand name Myfembree): Both are FDA-approved for heavy menstrual bleeding from fibroids. The ELARIS trials showed that elagolix with add-back therapy reduced menstrual blood loss by more than 50 percent in 68 percent of women over 6 months compared with 8.7 percent on placebo. Both are approved for up to 24 months. Neither is for use in pregnancy.
• Tranexamic acid (Lysteda): A non-hormonal option taken only during menstruation that reduces blood loss by about 40 percent. Suitable for women who cannot or prefer not to use hormonal therapy.
• NSAIDs: Reduce menstrual blood loss modestly (by about 20 to 30 percent) and help with pain. Best used as an adjunct, not a sole therapy for heavy bleeding.

Caregivers should know that most medical treatments control symptoms without eliminating fibroids. Fibroids typically return to their original size within months of stopping GnRH therapy.

Minimally Invasive Procedures

Uterine fibroid embolization (UFE): An interventional radiology procedure that cuts off blood supply to fibroids, causing them to shrink by 40 to 60 percent over 6 to 12 months. Recovery is typically 1 to 2 weeks. A long-term study in the American Journal of Obstetrics and Gynecology showed symptom relief in 85 to 90 percent of women at 5 years, though about 20 to 30 percent ultimately need additional treatment. UFE is generally not recommended for women actively trying to conceive, as its effect on uterine blood supply and implantation is not yet fully established.

Radiofrequency ablation (Acessa, Sonata): Uses ultrasound guidance and heat to destroy fibroid tissue. It is done laparoscopically (Acessa) or transcervically (Sonata) as a same-day procedure. Recovery is typically 3 to 5 days. Long-term fertility data are still limited.

Focused ultrasound (MR-HIFU): Non-invasive, uses MRI-guided high-intensity ultrasound to heat and destroy fibroid tissue. Usually requires multiple sessions. Not widely available and not recommended for women planning pregnancy due to incomplete long-term fertility data.

Surgical Options

Hysteroscopic myomectomy: Day-surgery removal of submucosal fibroids through the cervix. No external incision. Recovery is usually 1 to 2 days.

Laparoscopic or robotic myomectomy: Removes intramural and subserosal fibroids through small incisions. Recovery is 2 to 3 weeks. Preferred over open surgery when technically feasible.

Open (abdominal) myomectomy: Required for very large or numerous fibroids. Recovery is 4 to 6 weeks. This is where caregiver support is most intensive. Plan for at least 2 weeks of household help.

Hysterectomy: Definitive cure. No fibroid recurrence is possible. Appropriate for women who have completed childbearing and have severe symptoms unresponsive to other treatments. Recovery from minimally invasive hysterectomy is 2 to 4 weeks; open hysterectomy is 6 to 8 weeks.

Pregnancy and Lactation Considerations

Fibroids themselves do not respond to a single drug requiring a formal pregnancy safety category in the way a pharmaceutical does, but several fibroid treatments carry specific reproductive warnings caregivers should know.

GnRH agonists and antagonists (leuprolide, elagolix, relugolix) are contraindicated in pregnancy. The FDA label for Oriahnn states that elagolix/estradiol/norethindrone acetate is contraindicated in women who are pregnant or may become pregnant. Women of reproductive age taking these medications must use a non-hormonal contraceptive method because the add-back estrogen component does not provide contraception. Pregnancy should be excluded before starting treatment.

Tranexamic acid: Category B equivalent under the old FDA system. Human data are limited in pregnancy, and it is generally avoided in the first trimester unless benefit clearly outweighs risk. It passes into breast milk in small amounts; caution is advised during lactation.

Levonorgestrel IUD: If pregnancy occurs with an IUD in place, the device should be removed as soon as possible. It is not indicated in confirmed pregnancy.

Myomectomy: Performed only in pregnancy under extreme circumstances due to hemorrhage risk. Surgeons typically wait until after delivery.

After delivery, women who had significant fibroids during pregnancy face higher postpartum hemorrhage risk. Caregivers should know the warning signs: soaking more than one pad per hour, dizziness, or rapid heart rate after delivery are reasons to contact the obstetric team immediately.

Who Benefits From Which Treatment: A Life-Stage Summary

| Life Stage | Priority | First-Line Consideration | |---|---|---| | Reproductive years, no pregnancy plans | Symptom control | LNG-IUD, tranexamic acid, or GnRH antagonist with add-back | | Trying to conceive | Fertility preservation | Submucosal: hysteroscopic myomectomy. Intramural (large): laparoscopic myomectomy | | Pregnant | Safety, monitoring | Watchful waiting; analgesia for degeneration pain | | Perimenopause | Bridge to natural resolution | GnRH antagonist with add-back, UFE, or myomectomy if severe | | Post-menopause | Rule out malignancy if growing | Surveillance; treat only if symptomatic |

Practical Caregiver Action Plan

Supporting someone through fibroid diagnosis and treatment is not a passive role. Here is what actually helps.

Before and During Appointments

• Attend at least one specialist appointment. A second set of ears catches information that gets missed under stress.
• Prepare a written symptom log: number of pads or tampons used per day during the heaviest period days, clot size, and any days missed from work. This data changes clinical decisions.
• Write down questions in advance. ACOG recommends shared decision-making as the standard for fibroid management, which means the clinician needs to know what matters to her: fertility, avoiding surgery, returning to work quickly, or controlling bleeding long-term.

During Treatment and Recovery

• For outpatient procedures (hysteroscopy, radiofrequency ablation): plan to drive her home and stay for the first 24 hours.
• For UFE: expect the first 24 to 48 hours to involve significant cramping (called postembolization syndrome). Heat packs, prescribed NSAIDs, and someone to check in frequently are the primary needs.
• For open myomectomy or hysterectomy: 2 weeks of continuous household support is not excessive. Include meal preparation, childcare, laundry, and transportation to follow-up visits.
• Watch for signs of infection: fever above 38°C (100.4°F), increasing abdominal pain after the first week, abnormal discharge, or difficulty urinating. These warrant immediate contact with her surgical team.

Emotional and Relational Support

Fibroids affect body image, sexual health (dyspareunia is common, affecting an estimated 40 percent of women with fibroids), and fertility. Grief about lost fertility after hysterectomy is real and should not be minimized. Ask directly: "How are you feeling about what's ahead?" rather than assuming she is fine because the diagnosis is "benign."

As WomanRx clinician reviewer Dr. Rachel Goldberg notes: "Caregivers often underestimate how much the emotional weight of fibroid treatment, especially the prospect of hysterectomy before a woman feels finished with childbearing, can overshadow the physical recovery. The most useful thing a partner or family member can do is stay in the conversation rather than treating the diagnosis as solved once treatment is scheduled."

Questions to Bring to the Specialist

These are specific questions that change management decisions. Print this list and bring it to the appointment.

1. Are my fibroids distorting my uterine cavity? (This determines fertility impact.)
2. What is my current hemoglobin and ferritin level?
3. Do I need to treat my iron deficiency before any procedure?
4. How long will I need to be off work after this procedure?
5. What is the fibroid recurrence rate after this treatment in someone my age?
6. If I want to get pregnant within 2 years, which option protects that goal best?
7. Will this treatment affect my ability to use hormone therapy for menopause if I need it later?